TAILORx: Transforming the Treatment of Breast Cancer
The long-awaited results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) definitively identified the vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.
World Class Commercial Channel
We deliver over 400 Oncotype DX test results per day to more than 90 countries through our centralised clinical laboratory, serving physicians and patients with our industry-leading customer service team and more than 200 sales and managed care representatives around the world.